Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00910351 · ClinicalTrials.gov registry record · Phase 1

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

A Phase 1 study, sponsored by Bayer.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target

NCT00910351: Completed Phase 1 study, sponsored by Bayer.

NCT00910351 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00910351, a Phase 1 study, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target

Study Summary

Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.

Interventions

  • DRUG Ciprofloxacin (Cipro, BAYQ3939)

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2009-07
Est. Completion 2010-10
Phase Phase 1
Bayer

591 total trials

What the finished NCT00910351 record still lists

NCT00910351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 1 intervention - of which Ciprofloxacin (Cipro, BAYQ3939) is the first listed.

NCT00910351 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00910351 about?

NCT00910351 is a clinical study titled "Cipro Inhaler for Cystic Fibrosis Children Ages 6-12". Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population ...

What is the current status of trial NCT00910351?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2009-07. Estimated completion is 2010-10.

What interventions are being tested in trial NCT00910351?

The interventions under investigation include: Ciprofloxacin (Cipro, BAYQ3939) (DRUG).

Who is sponsoring clinical trial NCT00910351?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00910351's enrollment target sits among peer trials

19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00910351, the US trial registry maintained by the National Library of Medicine. NCT00910351 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.